AstraZeneca PLC’s BRILINTA® (ticagrelor) Added to American College of Chest Physicians Recommendations on Antithrombotic Therapy and Prevention of Thrombosis

Published: Feb 21, 2012

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) announced today that the American College of Chest Physicians (ACCP) has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to include a recommendation for giving the oral antiplatelet medicine, BRILINTA® (ticagrelor) tablets with low-dose aspirin to patients who suffer from Acute Coronary Syndrome (ACS).

Back to news